Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit

Rhea-AI Summary

Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022. Co-founder and Chief Scientific Officer Adi Mor will be a panelist. The discussion will focus on 'Platforms and Pipelines in a Product', highlighting potential applications across various rare diseases. Chemomab specializes in innovative therapies for fibrotic and inflammatory diseases, with their lead product, CM-101, in Phase 2 trials for multiple conditions.

TEL AVIV, Israel, March 23, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.

Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab, will participate in the panel.

Cantor Fitzgerald Rare Orphan Disease Summit (virtual)

Panel:               Platforms and Pipelines in a Product: How One Concept Could Have Multiple Applications Across Rare Diseases

Presenter:         Dr. Adi Mor, Chemomab co-founder and Chief Scientific Officer

Date:                March 29, 2022   

Time:                9:00 am – 10:15 am ET

Please reach out to your Cantor Fitzgerald representative to access the Rare Orphan Disease Summit.

About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 clinical trials—one in primary sclerosing cholangitis and the second in liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in 2022. For more information on Chemomab, visit www.chemomab.com.

Contacts:

Investor Relations:	Media:
Irina Koffler	Barbara Lindheim
LifeSci Advisors, LLC	Chemomab Therapeutics
Phone: +1-917-734-7387	Consulting Vice President
ir@chemomab.com	Investor & Public Relations,
	Strategic Communications
	Phone: +1-917-355-9234
	barbara@chemomab.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-cantor-fitzgerald-rare-orphan-disease-summit-301508580.html

SOURCE Chemomab Therapeutics, Ltd.

FAQ

When will Chemomab participate in the Cantor Fitzgerald Rare Orphan Disease Summit?

Chemomab will participate in the Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.

Who will represent Chemomab at the Rare Orphan Disease Summit?

Adi Mor, PhD, co-founder and Chief Scientific Officer, will represent Chemomab.

What is the focus of the panel discussion at the Rare Orphan Disease Summit?

The panel discussion is titled 'Platforms and Pipelines in a Product', focusing on applications across rare diseases.

What is Chemomab's main area of focus?

Chemomab focuses on developing therapeutics for fibrotic and inflammatory diseases with high unmet need.

What is CM-101 and its current status?

CM-101 is Chemomab's lead monoclonal antibody, currently in Phase 2 clinical trials for primary sclerosing cholangitis and liver fibrosis.